GSK China today committed to reduce the price of its first-line chronic hepatitis B (CHB) treatment, patent-protected Viread® (tenofovir disoproxil fumarate)1, in China by up to 67%. This follows an announcement on the outcomes of a national price negotiation pilot by the National Health and Family Planning Commission (NHFPC) and other relevant government agencies.
These press releases are intended for business journalists and analysts/investors
GSK delivers strong Q1 performance with sales of £6.2 billion (+8% CER), core EPS 19.8p (+8% CER); dividend of 19p.
2016 core EPS percentage growth now expected to be 10-12% CER.
In the publication of its 2015 Annual Report to shareholders, GSK plc announced that Sir Andrew Witty, CEO, has indicated to the Board his intention to retire from the company in early 2017.
GSK announced it will form a new public health institute in Beijing, to help China tackle the health threats posed by antibiotic resistance and infectious diseases.
GSK delivers further progress against strategy with 2015 sales of £24 billion (+6%), core EPS 75.7p (-15%) and total EPS 174.3p, +>100% CER
2016 core EPS percentage growth expected to reach double digits (CER)
Tivicay® (dolutegravir), an innovative HIV drug from ViiV Healthcare, has received approval from the China Food and Drug Administration (CFDA) for use in combination with other anti-retroviral medicinal products for the treatment of HIV infected adults and adolescents above 12 years of age.
Three-year partnership with National Health and Family Planning Commission underlines GSK’s commitment to medical education in China
3 year partnership with National Health and Family Planning Commission of China
Today GSK China announces a strategic private-public partnership with the National Health...